Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Sezary Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Peripheral Blood Stem Cell Transplantation 39fludarabine phosphate 36Cyclophosphamide 31Mycophenolic Acid 28Cyclosporine 25Whole-Body Irradiation 24Tacrolimus 22Busulfan 18Antilymphocyte Serum 18Radiotherapy 16Methotrexate 16Flow Cytometry 14Filgrastim 14Etoposide 13Methylprednisolone 10Lenalidomide 10Bortezomib 10Vorinostat 9Melphalan 9mogamulizumab 8Therapeutics 8Rituximab 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Gemcitabine 8Cord Blood Stem Cell Transplantation 7Bexarotene 7pembrolizumab 6Alemtuzumab 6tanespimycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡